RxDoctor Payments Data

Gladstone Sellers, MD

Internal Medicine · Atlanta, GANPI 1063521102

Payments from drug & device makers

$6,695in general payments, 2019–2025

Across 141 payments — averaging $47.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Amgen$1K
  • Pfizer$342
  • Lilly USA, LLC$330
  • Bristol Myers Squibb$224
  • plus $810 from 13 others

What the payments were for

  • Consulting fees$1,20018%
  • Speaking & faculty fees$2,25034%
  • Travel & lodging$561%
  • Food & beverage$3,18948%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,695 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$50,381
Medicare patients
127
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$44,523
OzempicSemaglutide13$29,064
Repatha SureclickEvolocumab19$17,988
JardianceEmpagliflozin17$16,701
MyrbetriqMirabegron15$10,454
LinzessLinaclotide15$9,003
LexaproEscitalopram Oxalate12$5,237
SynthroidLevothyroxine Sodium49$4,188
Levothyroxine Sodium192$2,615
Memantine Hcl ErMemantine Hcl12$2,606
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide34$2,424
Duloxetine Hcl55$1,794
Pravastatin Sodium90$1,632
Fentanyl12$1,376
Rosuvastatin Calcium108$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$342$44,52333 claims
Novo NordiskOzempic$50$29,06413 claims
AbbVieLinzess, Lexapro, Synthroid$2,625$18,42876 claims
Astellas Pharma US IncMyrbetriq$31$10,45415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →